Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
Dextromoramide
Dextromoramide is an opioid analgesic1, classified as a depressant and habit-forming substance. It emerged from research into related compounds and is the right-handed isomer of moramide. It is approximately three times more potent than morphine but shorter acting. Reports describe unusual, rapid tolerance behavior, and its habit-forming properties present dependence risk.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Dextromoramide is reported to have unpredictable effects and an unusually rapid tolerance development, which may complicate accurate dosing.
Duration
Subjective Effects
Pharmacology
Pharmacodynamics
Dextromoramide is a powerful opioid analgesic, reported to be approximately three times more potent than morphine. It has a shorter action than morphine2, while tolerance to its analgesic effects was reported to develop relatively slowly compared with most other short-acting opioids.
Pharmacokinetics
In nine surgical patients given a single oral dose with an anticholinergic, dextromoramide was rapidly absorbed from the gastrointestinal tract3. Taken orally, it is also reported to have a fast onset and high bioavailability, with oral dosing producing almost as much effect as injection. In five patients given oral dextromoramide with an anticholinergic, plasma concentrations declined after the peak with first-phase half-lives of 0.4–1.6 hours and terminal half-lives of 6.3–21.8 hours3. In the nine-patient oral-dose study, apparent volume of distribution values ranged from 0.6 to 2.4 L/kg3. In nine surgical patients given a single oral dose with an anticholinergic, peak plasma levels were usually reached within 0.5–4.0 hours after dosing3. In five of these patients, plasma concentrations declined after the peak in a biphasic pattern, with first-phase half-lives of 0.4–1.6 hours and terminal half-lives of 6.3–21.8 hours3. In the remaining patients, no clear-cut biphasic pattern was observed; half-lives calculated between 4 and 10 hours after administration ranged from 1.5 to 4.7 hours3. Less than 0.06% of the dose is excreted unchanged in urine within 8 hours3.
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Harm Potential
Addiction & Dependence
Psychological
HighDescribed as highly addictive with significant abuse potential. The substance was reportedly not returned to market in part due to concerns about its addictive properties as an oral painkiller.
Physical
HighDependence liability is similar to morphine, though the withdrawal syndrome is reportedly less severe than morphine withdrawal.
History & Culture
Discovery and development
Dextromoramide was discovered and patented in 1956 by Paul Janssen at Janssen Pharmaceuticals. Janssen was also associated with the development of several other notable medicines, including fentanyl and haloperidol.
Legality
References
Citations
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Dextromoramide article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.